Supplementary Table S1. SNPs and clinical outcome in subgroup recieving FOLFOX or oral fluoropyrimidine
Disease-free Survival Overall survival
Median, months (95%CI)
3-year of recurrence ± SE
HR (95%CI) † P
value*
HR (95%CI) ‡ P
value*
Median, months (95%CI)
5-year of survival ± SE
HR (95%CI) † P
value*
HR (95%CI) ‡ P
value*
FOLFOX subgroup CDX2
rs3812863
0.49 0.49
A/A 12 5.1+(1.7,5.1+) 0.26±0.13 1(Reference) 1(Reference)
A/G 33 5.5+(1.8,5.5+) 0.43±0.09 2.06(0.59,7.18) 2.07(0.59,7.22)
G/G 23 6.0+(2.5,6.0+) 0.35±0.10 1.59(0.42,5.99) 1.55(0.41,5.87) - - - -
0.30 0.32 0.61 0.82
A/A 12 5.1+(1.7,5.1+) 0.26±0.13 1(Reference) 1(Reference) 5.1+(4.3,5.1+) 0.75±0.32 1(Reference) 1(Reference)
Any G 56 6.0+(2.7,6.0+) 0.40±0.07 1.86(0.56,6.22) 1.84(0.55,6.16) 6.0+ 0.85±0.07 1.71(0.21,13.68) 1.28(0.15,10.85)
0.83 0.81
Any A 45 5.5+(2.7,5.5+) 0.38±0.07 1(Reference) 1(Reference)
G/G 23 6.0+(2.5,6.0+) 0.35±0.10 0.91(0.39,2.12) 0.90(0.38,2.10)
MS4A12 rs4939378
0.21 0.23 0.46 0.34
A/A 29 5.5+(1.5,5.5+) 0.42±0.09 1(Reference) 1(Reference) 5.9+ 0.85±0.11 1(Reference) 1(Reference)
A/G 29 6.0+ 0.24±0.08 0.49(0.19,1.25) 0.51(0.19,1.35) 6.0+ 0.93±0.09 0.49(0.09,2.69) 0.33(0.06,1.99)
G/G 9 2.9(1.0,5.0+) 0.56±0.17 1.18(0.42,3.36) 1.29(0.44,3.75) 5.0+(2.8,5.0+) 0.58±0.26 1.60(0.29,8.77) 1.35(0.24,7.61)
0.29 0.38 0.69 0.43
A/A 29 5.5+(1.5,5.5+) 0.42±0.09 1(Reference) 1(Reference) 5.9+ 0.85±0.11 1(Reference) 1(Reference)
Any G 38 6.0+ 0.32±0.08 0.65(0.29,1.45) 0.68(0.29,1.59) 6.0+ 0.86±0.11 0.75(0.19,3.01) 0.55(0.13,2.40)
0.32 0.26 0.34 0.33
Any A 58 6.0+ 0.33±0.06 1(Reference) 1(Reference) 6.0+ 0.89±0.06 1(Reference) 1(Reference)
G/G 9 2.9(1.0,5.0+) 0.56±0.17 1.63(0.61,4.38) 1.78(0.66,4.79) 5.0+(2.8,5.0+) 0.58±0.26 2.15(0.43,10.70) 2.24(0.45,11.15)
Oral fluoropyrimidine subgroup CDX2
rs3812863
0.43 0.85 0.35 0.75
A/A 49 7.0+ 0.35±0.07 1(Reference) 1(Reference) 8.6+ 0.82±0.08 1(Reference) 1(Reference)
A/G 98 8.0+ 0.24±0.04 0.68(0.37,1.27) 0.85(0.45,1.59) 8.0+ 0.86±0.07 0.63(0.25,1.60) 1.15(0.44,3.00)
G/G 58 7.6+(6.3,7.6+) 0.21±0.05 0.70(0.35,1.39) 0.85(0.42,1.71) 8.0+ 0.93±0.05 0.43(0.13,1.44) 0.72(0.22,2.43)
0.20 0.57 0.18 0.96
A/A 49 7.0+ 0.35±0.07 1(Reference) 1(Reference) 8.6+ 0.82±0.08 1(Reference) 1(Reference)
Any G 156 8.0+ 0.23±0.03 0.69(0.39,1.22) 0.85(0.47,1.51) 8.0+ 0.88±0.05 0.56(0.23,1.33) 0.98(0.40,2.38)
0.69 0.84 0.30 0.48
Any A 147 8.0+ 0.28±0.04 1(Reference) 1(Reference) 8.6+ 0.85±0.05 1(Reference) 1(Reference)
G/G 58 7.6+(6.3,7.6+) 0.21±0.05 0.89(0.49,1.60) 0.94(0.52,1.70) 8.0+ 0.93±0.05 0.57(0.19,1.69) 0.67(0.23,2.00)
MS4A12 rs4939378
0.71 0.67 0.15 0.13
A/A 63 7.4+ 0.24±0.05 1(Reference) 1(Reference) 7.4+ 0.89±0.06 1(Reference) 1(Reference)
A/G 96 8.0+(6.3,8.0+) 0.23±0.04 0.93(0.50,1.73) 0.87(0.46,1.62) 8.0+ 0.92±0.04 0.81(0.27,2.41) 0.67(0.22,2.01)
G/G 40 8.0+ 0.28±0.07 1.24(0.59,2.61) 1.19(0.57,2.51) 8.6+(5.7,8.6+) 0.73±0.14 2.12(0.71,6.30) 2.00(0.66,6.04)
0.96 0.87 0.75 0.98
A/A 63 7.4+ 0.24±0.05 1(Reference) 1(Reference) 7.4+ 0.89±0.06 1(Reference) 1(Reference)
Any G 136 8.0+ 0.25±0.04 1.02(0.57,1.81) 0.95(0.54,1.70) 8.6+ 0.86±0.06 1.17(0.45,3.05) 1.01(0.39,2.63)
0.42 0.43 0.056 0.055
Any A 159 8.0+ 0.23±0.03 1(Reference) 1(Reference) 8.0+ 0.91±0.03 1(Reference) 1(Reference)
G/G 40 8.0+ 0.28±0.07 1.30(0.68,2.47) 1.30(0.68,2.48) 8.6+(5.7,8.6+) 0.73±0.14 2.39(0.95,5.99) 2.51(0.98,6.46)
* P value was based on log-rank test for PFS and OS in the univariate analysis (†) and Wald test for DFS and OS in the multivariable Cox regression model adjusted for UICC Stage (IIIB vs IIIC), adjuvant chemotherapy (yes vs.
no), histological differentiation (well, moderate, poor) (‡).
+ Estimates not reach.
- No events.
